Human Recombinant Insulin Market What Factors will drive the Market in Upcoming Years and How it is Going to Impact on Global Industry

Human Recombinant Insulin Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players of the Human Recombinant Insulin Industry.

Human Recombinant Insulin Market report provides emerging opportunities in the market and the future impact of major drivers and challenges and, support decision makers in making cost-effective business decisions. One of the objectives of this report is to identify the latest developments, market shares, and strategies employed by the major market players. Besides, the least competitive market niches with significant growth potential are also identified. For research methodology, secondary research, primary research, subject matter expert advice, quality check, and final review was utilized.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1797

Insulin’s discovery is regarded as amongst the most vital events within history of treatment of diabetes. Moreover, major developments in the technology of human insulin are the human insulin analogue synthesis through recombinant technology. Presently, delivery system of human insulin available for insulin’s administration include jet injections, insulin pumps, pens, and insulin syringes. Major players are engaged on development of recombinant human insulin rather than animal-based insulin, due to rising demand of human insulin for diabetes treatment. Human recombinant insulin consists a faster action onset and lesser immunogenicity as compared with beef or pork insulin. Presently the human recombinant insulin is receiving significant traction along with the advancement of human insulin’s biosimilar analogue.

As per the 2016 report by Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): the market of insulin such as human recombinant insulin greatly contributes over 40 local companies, largely with local markets besides the three largest manufactures of global insulin: Novo Nordisk A/S, Eli Lilly and Company, and Sanofi S.A. Moreover, various manufacturers provide recombinant analog of the insulin-like human growth factor which has been particularly engineered for industrial cell culture market and research, offering a consistent, reliable, and compliant alternative for recombinant insulin. The manufacturers include: Thermo Fisher Scientific, Inc., Merck KGaA, among others. Such manufacturers offers products of recombinant human insulin analogue as the raw material or mixed with custom formulations of media for applications of commercial bio-manufacturing and process development at small-scale. Introduction of biosimilar along with other products of insulin and research of products for recombinant insulin is expected to propel the global human recombinant insulin market growth over the forecast period.

Furthermore, rising population of diabetes, globally along with rising R&D activities through various private and government organizations in development of human insulin is expected to drive the global human recombinant insulin market growth in the near future.

The global human recombinant insulin market accounted for US$ 27.4 billion in 2018, and is projected to exhibit a 7.2% CAGR over the forecast period (2018 – 2026).

Global Human Recombinant Insulin Market – Dynamics

Increasing Investment in Diabetes Research Activities is expected to boost the Growth of Human Recombinant Insulin Market

Several private and government research organizations are focused on activities of R&D to develop advanced treatments in diabetes-care for increasing the human insulin’s effectiveness, reducing diabetes burden, along with minimizing the threat of disorders associated with diabetes including diabetes-associated blindness, heart attacks, kidney disease, limb loss, or strokes. For instance, the American Diabetes Association (ADA) funded US$ 807.4 Mn in over 4,700 projects for diabetes research from 1952 to 2017. As per the 2017 review by ADA, ADA invested over US$ 37.4 Mn for the diabetes research in 2017, along with supporting 371 research projects related to diabetes. The European Foundation for the Study of Diabetes (EFSD), a European Association for the Study of Diabetes’ (EASD) division, offers funding initiatives in every area of the diabetes research. The EFSD aims at accelerating and supporting research within the diabetes field for introducing innovative portfolio of diabetic management.

Biocon Limited, a biopharmaceutical firm based in India, in September 2017, received funding by the Juvenile Diabetes Research Foundation (JDRF) for studying Tregopil, a candidate of oral insulin drug, for evaluating the tolerability and safety in people having diabetes of type 1. The collaboration among JDRF and Biocon is an aspect of Industry Discovery and Development Partnership (IDDP) programme by JDRF, by which JDRF offers financial support for Biocon for accelerating research in diabetes management of type 1.

Purchase this Premium Report With Discount – https://www.coherentmarketinsights.com/promo/buynow/1797

Increasing prevalence of diabetes is a key factor is expected to drive the global human recombinant insulin market growth in the near future. For instance, as per the World Health Organization (WHO), in 2016, over 422 Mn adults have diabetes. A major surge in type 2 diabetes prevalence during the past decade is majorly attributed to rising incidence of obesity. As per the International Diabetes Federation (IDF) Atlas, in 2017, the global diabetes burden is affecting over 425 million populace, from which 33% are aged 65 years and above. Furthermore, the populace of diabetic people may increase to 629 Mn in 2045. Moreover, 352 Mn people having impaired tolerance of glucose are more likely to develop diabetes. Continuous rise in diabetes’ incidence rate, due to unhealthy lifestyles, obesity, binge eating, physical inactivity, along with insulin resistivity in global populace is further expected to boost the global human recombinant insulin market growth over the forecast period.

However, insulin’s high cost is expected to restrain the global human recombinant insulin market growth in the near future, as people from middle and low income countries cannot afford it. As per the May 2018 report by Pharmaceutical Care Management Association (PCMA), insulin’s prices have surged over 10-times from 1985 and the prices have projected significant rise over the past decade (2008 to 2018). As per the PCMA, Humulin/Novolin prices have raised from over US$ 25/prescription (1985) to over US$ 300 (2016). Moreover, long-acting insulin prices have surged from over US$ 100/prescription (2007) to over US$ 400 (2016).

Major Players Are Operating In This Market Are: Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.

Highlights of the Human Recombinant Insulin report:

1. A complete backdrop analysis, which includes an assessment of the Human Recombinant Insulin Market
2. An objective assessment of the trajectory of the market
3. Market segmentation up to the second or third level
4. Reporting and evaluation of recent industry developments
5. Important changes in market dynamics
6. Emerging niche segments and regional markets
7. Historical, current, and projected size of the market from the standpoint of both value and volume
8. Market shares and strategies of key players
9. Recommendations to companies for strengthening their foothold in the market

To conclude, the Human Recombinant Insulin Market report mentions the key geographies, market landscapes alongside the production and consumption analysis, supply and demand analysis, market growth rate, along with future forecast etc. This report also provides SWOT and PEST analysis, investment feasibility and return analysis. Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.